PPI

Between the months of April and May 2023, Penta hosted advisory group meetings where young people between the ages of 15 and 19 from South Africa, Argentina, the United Kingdom and Thailand, were invited to share their experiences and knowledge of long-acting injectable antiretrovirals at local in-person consultation workshops. The young people all had recent experience in paediatric HIV care and joined in the discussions about the acceptability, challenges and solutions of adopting and using long-acting injectables for themselves and their peers and how this could support or impact their transition to adult care.

Authors: Burke, T; Conway, M

Presented at: AIDS 2022 an the International Workshop on HIV & Adolescence 2022

Authors: Cebekhulu, S; Shibemba, M; Conway, M; Kiganda, C; Ahimbisibwe, Bhiri, J; Carter, A; Ely, A; Gondo, S; Nkosi, N.

Presented at: AIDS 2022 and International Workshop on HIV & Adolescence 2022

Authors: Folayan MO, Conway M, Russo C, Diniz N, Jafta LP, Sam-Agudu NA, Bernays S, Santana VM, Epps C, Turner MA

Published in: Springer

Involving patients in our clinical trials is of utmost importance to us. Penta is dedicated to ensuring that the young people in our trials are included at various stages of the research process. In late April 2022, Mercy Shibemba, one of our PPI experts, sat down with two members of our Youth Trials Board (YTB) to talk about the work that they do and what it’s like to participate in clinical trials as young people living with HIV.